Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) Shares Outstanding (2016 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed Shares Outstanding for 16 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 111.71% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, up 111.71% year-over-year, with the annual reading at $3.7 million for FY2025, 111.71% up from the prior year.
  • Shares Outstanding for Q4 2025 was $3.7 million at Creative Medical Technology Holdings, up from $2.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $3.7 million in Q4 2025, with the low at $1.0 in Q3 2024.
  • Average Shares Outstanding over 5 years is $1.6 million, with a median of $1.4 million recorded in 2023.
  • Peak annual rise in Shares Outstanding hit 4527657.14% in 2021, while the deepest fall reached 99.11% in 2021.
  • Over 5 years, Shares Outstanding stood at $633886.0 in 2021, then soared by 122.06% to $1.4 million in 2022, then grew by 1.67% to $1.4 million in 2023, then increased by 22.17% to $1.7 million in 2024, then surged by 111.71% to $3.7 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $3.7 million, $2.6 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.